Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma

Seminars in Oncology

Volumn 29, Issue 2 SUPPL. 6, 2002, Pages 18-22

  Coiffier, Bertrand ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CARDIOTOXICITY; CELL SPECIFICITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELDERLY CARE; FEMALE; FEVER; FOLLOW UP; HUMAN; INFECTION; LIVER TOXICITY; LUNG TOXICITY; MALE; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STANDARD; STATISTICAL ANALYSIS;

EID: 0036264255     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.32749     Document Type: Conference Paper

References (22)

1. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes
2. A predictive model for aggressive non-Hodgkin's lymphoma
3. Effect of age on the characteristics and clinical behaviour of non-Hodgkin's lymphoma patients
4. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
5. Non-Hodgkin's lymphomas
6. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol. A Groupe d'Étude des Lymphomes de l'Adulte study
7. A randomized comparison of ACVBP and CHOP in the treatment of advanced aggressive non-Hodgkin's lymphoma: The LNH93-5 study
8. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma
9. Comparison of doxorubicin and mixantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
10. Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the UK
11. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
12. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
13. IDEC-C2B8 (Rituximab) anti-CD-20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
14. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
15. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias
16. Cladribine in the treatment of low-grade non-Hodgkin's lymphoma
17. Fludarabine phosphate in lymphoma: An important new therapeutic agent
18. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
19. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
20. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's Lymphoma
21. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial
22. Updated results of the GELA randomized trial comparing rituximab plus CHOP (R-CHOP) to CHOP in elderly patients with diffuse large B-cell lymphoma (DLCL)